Rachel Richman
Overview
With a focus on White Collar and Regulatory Enforcement and International Trade, Rachel Richman assists clients—from startups to large corporations—in navigating government investigations and regulatory challenges.
Career & Education
- Department of Commerce
Law Clerk, Commercial Law Development Program, 2023 - Securities and Exchange Commission
Law Clerk, Division of Enforcement, FCPA Unit, 2022 - New York
Law Clerk, Medicaid Fraud Control Unit, Office of the New York Attorney General, 2022
- Department of Commerce
Jacob Burns Community Legal Clinics, Criminal Defense and Justice Clinic, 2024
- The George Washington University, J.D., 2024
- Tulane University, B.S., cum laude, in Legal Studies in Business, minor in Art History, 2020
- District of Columbia
- Russian
- Hebrew
- Spanish
Rachel's Insights
Client Alert | 3 min read | 01.21.26
Atlantic Biologicals Opioid DPA: DOJ Continues Ramp Up of Criminal Corporate Healthcare Enforcement
On January 13, 2026, Miami-based pharmaceutical wholesaler Atlantic Biologicals Corporation entered into a two-year DPA, admitting to conspiracy to distribute and dispense controlled substances, including more than 14 million opioid doses to “pill mill” pharmacies in Texas at a markup. The DOJ and DEA underscored the company’s deliberate evasion of compliance checks and disregard for red flags signaling diversion.
Client Alert | 8 min read | 10.01.25
Representative Matters
Crypto and Financial Services Industry
- Conducts comprehensive internal investigations relating to market manipulation, fraud, money laundering, and other compliance concerns raised by whistleblowers, government agencies, and other stakeholders, including managing all phases of the investigative process, coordinating document review and witness interviews, and providing actionable recommendations to mitigate risk and strengthen regulatory compliance frameworks.
- Represents clients in enforcement actions, regulatory inquiries, and criminal proceedings before OFAC, the DOJ, the FTC, FinCEN, and other federal agencies, including responding to subpoenas and civil investigative demands, negotiating resolutions, and developing and implementing tailored compliance programs to address regulatory obligations and reduce exposure to future enforcement risk.
Tariffs and Customs Advocacy
- Advises clients on the application of current and evolving tariff schemes to their businesses, including analyzing tariff classifications, assessing duty exposure, and developing strategic approaches to minimize costs and ensure compliance with applicable trade regulations.
- Advocates on clients’ behalf before U.S. Customs and Border Protection on a range of matters, including tariff classification disputes, valuation issues, country of origin determinations, and duty drawback claims, achieving favorable outcomes that optimize their trade and import operations.
Defense and Manufacturing Sectors
- Guides clients through all phases of OFAC-related matters, including government investigations, internal investigations, voluntary self-disclosures, and the development and implementation of robust sanctions compliance programs to ensure adherence to U.S. regulatory requirements.
- Advises clients on all aspects of export controls and sanctions compliance, including navigating the International Traffic in Arms Regulations (ITAR) and Export Administration Regulations (EAR), conducting regulatory assessments, and developing and implementing trade compliance to mitigate risk and prevent costly trade disruptions.
Pro Bono Engagements
- Involved in advocating for asylum seekers through pro bono work, providing legal representation, and achieving positive outcomes in immigration proceedings, showcasing a dedication to justice and community service.
Rachel's Insights
Client Alert | 3 min read | 01.21.26
Atlantic Biologicals Opioid DPA: DOJ Continues Ramp Up of Criminal Corporate Healthcare Enforcement
On January 13, 2026, Miami-based pharmaceutical wholesaler Atlantic Biologicals Corporation entered into a two-year DPA, admitting to conspiracy to distribute and dispense controlled substances, including more than 14 million opioid doses to “pill mill” pharmacies in Texas at a markup. The DOJ and DEA underscored the company’s deliberate evasion of compliance checks and disregard for red flags signaling diversion.
Client Alert | 8 min read | 10.01.25
Insights
- |
10.07.25
Crowell & Moring’s International Trade Law
- |
07.07.25
Crowell & Moring’s International Trade Law
Rachel's Insights
Client Alert | 3 min read | 01.21.26
Atlantic Biologicals Opioid DPA: DOJ Continues Ramp Up of Criminal Corporate Healthcare Enforcement
On January 13, 2026, Miami-based pharmaceutical wholesaler Atlantic Biologicals Corporation entered into a two-year DPA, admitting to conspiracy to distribute and dispense controlled substances, including more than 14 million opioid doses to “pill mill” pharmacies in Texas at a markup. The DOJ and DEA underscored the company’s deliberate evasion of compliance checks and disregard for red flags signaling diversion.
Client Alert | 8 min read | 10.01.25




